Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 2.52
LPDX's Cash to Debt is ranked higher than
68% of the 254 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.82 vs. LPDX: 2.52 )
LPDX' s 10-Year Cash to Debt Range
Min: 0.66   Max: No Debt
Current: 2.52

Equity to Asset 0.62
LPDX's Equity to Asset is ranked higher than
71% of the 234 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.63 vs. LPDX: 0.62 )
LPDX' s 10-Year Equity to Asset Range
Min: -1.71   Max: 0.71
Current: 0.62

-1.71
0.71
F-Score: 3
Z-Score: 1.17
M-Score: -3.36
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -26.56
LPDX's Operating margin (%) is ranked higher than
63% of the 251 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.33 vs. LPDX: -26.56 )
LPDX' s 10-Year Operating margin (%) Range
Min: -20.39   Max: 10.35
Current: -26.56

-20.39
10.35
Net-margin (%) -30.65
LPDX's Net-margin (%) is ranked higher than
63% of the 251 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.44 vs. LPDX: -30.65 )
LPDX' s 10-Year Net-margin (%) Range
Min: -23.93   Max: 10.95
Current: -30.65

-23.93
10.95
ROE (%) -28.95
LPDX's ROE (%) is ranked higher than
61% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.21 vs. LPDX: -28.95 )
LPDX' s 10-Year ROE (%) Range
Min: -305.66   Max: -305.66
Current: -28.95

ROA (%) -18.89
LPDX's ROA (%) is ranked higher than
62% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.22 vs. LPDX: -18.89 )
LPDX' s 10-Year ROA (%) Range
Min: -20.95   Max: 42.82
Current: -18.89

-20.95
42.82
ROC (Joel Greenblatt) (%) -69.49
LPDX's ROC (Joel Greenblatt) (%) is ranked higher than
65% of the 255 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. LPDX: -69.49 )
LPDX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -80.07   Max: 189.36
Current: -69.49

-80.07
189.36
» LPDX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

LPDX Guru Trades in Q4 2013

Jim Simons 79,400 sh (New)
Wilbur Ross 724,213 sh (unchged)
» More
Q1 2014

LPDX Guru Trades in Q1 2014

Jim Simons 120,522 sh (+51.79%)
Wilbur Ross 724,213 sh (unchged)
» More
Q2 2014

LPDX Guru Trades in Q2 2014

Jim Simons 163,700 sh (+35.83%)
Wilbur Ross 724,213 sh (unchged)
» More
Q3 2014

LPDX Guru Trades in Q3 2014

Mario Gabelli 20,000 sh (New)
Jean-Marie Eveillard 200,000 sh (New)
Jim Simons 190,000 sh (+16.07%)
Wilbur Ross 724,213 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with LPDX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Mario Gabelli 2014-09-30 New Buy$2.83 - $5.19 $ 5.2462%20000
Jean-Marie Eveillard 2014-09-30 New Buy$2.83 - $5.19 $ 5.2462%200000
Wilbur Ross 2013-03-31 New Buy0.73%$9.6 - $11.33 $ 5.24-50%724213
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.07
LPDX's P/B is ranked higher than
87% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.46 vs. LPDX: 2.07 )
LPDX' s 10-Year P/B Range
Min: 1   Max: 2.81
Current: 2.07

1
2.81
P/S 1.88
LPDX's P/S is ranked higher than
82% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.11 vs. LPDX: 1.88 )
LPDX' s 10-Year P/S Range
Min: 0.27   Max: 1.88
Current: 1.88

0.27
1.88
EV-to-EBIT -4.95
LPDX's EV-to-EBIT is ranked lower than
58% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. LPDX: -4.95 )
LPDX' s 10-Year EV-to-EBIT Range
Min: -60.7   Max: -1.4
Current: -4.95

-60.7
-1.4
Current Ratio 4.73
LPDX's Current Ratio is ranked higher than
86% of the 250 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.56 vs. LPDX: 4.73 )
LPDX' s 10-Year Current Ratio Range
Min: 1.21   Max: 11.5
Current: 4.73

1.21
11.5
Quick Ratio 4.70
LPDX's Quick Ratio is ranked higher than
88% of the 250 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.16 vs. LPDX: 4.70 )
LPDX' s 10-Year Quick Ratio Range
Min: 1.21   Max: 11.47
Current: 4.7

1.21
11.47

Valuation & Return

vs
industry
vs
history
Price/Net Cash 4.99
LPDX's Price/Net Cash is ranked higher than
94% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. LPDX: 4.99 )
LPDX' s 10-Year Price/Net Cash Range
Min: 2.23   Max: 4.93
Current: 4.99

2.23
4.93
Price/Net Current Asset Value 4.23
LPDX's Price/Net Current Asset Value is ranked higher than
94% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. LPDX: 4.23 )
LPDX' s 10-Year Price/Net Current Asset Value Range
Min: 1.85   Max: 4.18
Current: 4.23

1.85
4.18
Price/Tangible Book 2.11
LPDX's Price/Tangible Book is ranked higher than
91% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.28 vs. LPDX: 2.11 )
LPDX' s 10-Year Price/Tangible Book Range
Min: 1.07   Max: 2.85
Current: 2.11

1.07
2.85
Price/Median PS Value 2.02
LPDX's Price/Median PS Value is ranked higher than
64% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.36 vs. LPDX: 2.02 )
LPDX' s 10-Year Price/Median PS Value Range
Min: 0.43   Max: 2
Current: 2.02

0.43
2
Earnings Yield (Greenblatt) -20.20
LPDX's Earnings Yield (Greenblatt) is ranked higher than
54% of the 248 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.80 vs. LPDX: -20.20 )
LPDX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0   Max: 0
Current: -20.2

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare: » details
Traded in other countries:LI0.Germany
LipoScience Inc was incorporated under the laws of North Carolina in June 1994 under the name LipoMed, Inc. and reincorporated under the laws of Delaware in June 2000. The Company is a clinical diagnostic company into field of personalized diagnostics based on nuclear magnetic resonance technology. The Company's first diagnostic test, the NMR LipoProfile test, is cleared by the U.S. Food and Drug Administration, and directly measures the number of low density lipoprotein, particles in a blood sample and provides physicians and their patients with actionable information to personalize management of risk for heart disease. The Company's technology platform combines proprietary signal processing algorithms and NMR spectroscopic detection into a clinical analyzer to identify and quantify concentrations of lipoproteins and, potentially, small molecule metabolites. NMR detectors, or spectrometers, analyze a blood plasma or serum sample by subjecting it to a short pulse of radio frequency energy within a strong magnetic field. The Company currently markets NMR LipoProfile test through a direct sales force in 27 states. The Company competes against companies that offer other methods for measuring lipoproteins. Its competitors include Quest Diagnostics, Berkeley HeartLab, Inc., Atherotech, Inc. and SpectraCell Laboratories. The Company is subject to extensive and frequently changing federal, state and local laws and regulations governing various aspects of its business.
» More Articles for LPDX

Headlines

Articles On GuruFocus.com
Distressed Investor Wilbur Ross Buys 2 Stocks May 16 2013 

More From Other Websites
Nasdaq stocks posting largest volume increases Nov 25 2014
LIPOSCIENCE INC Financials Nov 21 2014
LIPOSCIENCE INC Files SEC form 8-K, Termination of a Material Definitive Agreement, Completion of... Nov 21 2014
LabCorp Completes Acquisition of LIPOSCIENCE Nov 21 2014
LabCorp Completes Acquisition of LIPOSCIENCE Nov 21 2014
LipoScience Announces 2014 Third Quarter Financial Results Nov 12 2014
LIPOSCIENCE INC Files SEC form 8-K, Results of Operations and Financial Condition Nov 12 2014
LipoScience Announces 2014 Third Quarter Financial Results Nov 12 2014
Q3 2014 LipoScience Inc Earnings Release - Tentative - Time Not Supplied Nov 03 2014
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of LipoScience, Inc. of Class Action... Oct 20 2014
LabCorp’s Acquisition of LipoScience Clears Antitrust Approval Oct 15 2014
LabCorp's Acquisition of LipoScience Clears Antitrust Approval Oct 15 2014
LabCorp's Acquisition of LipoScience Clears Antitrust Approval Oct 15 2014
LIPOSCIENCE SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate... Oct 15 2014
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of LipoScience, Inc. in Connection... Oct 14 2014
SHAREHOLDER ALERT – The Law Offices of Vincent Wong Investigates the Board of Directors of... Oct 14 2014
Lifshitz & Miller Law Firm Announces Investigation of AcelRx Pharmaceuticals, Inc., Ambit... Oct 07 2014
SHAREHOLDER ALERT - The Law Offices of Vincent Wong Investigates the Board of Directors of... Oct 07 2014
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of LipoScience, Inc. in Connection... Oct 04 2014
INVESTOR ALERT: Levi & Korsinsky, LLP Launches Investigation of the Board of Directors of... Oct 02 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK